Ulinastatin-mediated protection against zymosan-induced multiple organ dysfunction in rats

Biologicals

Volumn 38, Issue 5, 2010, Pages 552-556

  Yang, Qiuping ^a   Liu, Xingang ^a   Liu, Min ^a   Zhang, Ling ^a   Guan, Yinghui ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

MODS; Multiple organ dysfunction syndrome; Polysaccharide; TLR4; Toll like receptor 4; Ulinastatin; Zymosan

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LUNG; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL; TISSUE LEVEL; VALIDATION PROCESS;

ANIMALS; CYTOPROTECTION; FEMALE; GLYCOPROTEINS; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; LIVER; LUNG; MALE; MULTIPLE ORGAN FAILURE; RATS; RATS, WISTAR; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 4; TRYPSIN INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA; ZYMOSAN;

RATTUS; RATTUS NORVEGICUS;

EID: 77956227340     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2010.05.001     Document Type: Article

References (30)

1. Marshall J.C. The multiple organ dysfunction syndrome. Surgical Treatment: Evidence-based and problem-oriented 2001, 780-785. Zuckschwerdt Verlag, Munich. R.G. Holzheimer, J.A. Mannick (Eds.).
2. Townsend S., Schorr C., Levy M., Dellinger R. Reducing mortality in severe sepsis: the Surviving Sepsis Campaign. Clin Chest Med 2008, 29:721-733.
3. Papathanassoglou E., Bozas E., Giannakopoulou M. Multiple organ dysfunction syndrome pathogenesis and care: a complex systems' theory perspective. Nurs Crit Care 2008, 13:249-259.
4. Mizock B. The multiple organ dysfunction syndrome. Dis Mon 2009, 55:476-526.
5. Bromke B., Kueppers F. The major urinary protease inhibitor: simplified purification and characterization. Biochem Med 1982, 27:56-67.
6. Hirose J., Ozawa T., Miura T., Isaji M., Nagao Y., Yamashiro K., et al. Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull 1998, 21:651-656.
7. Umeadi C., Kandeel F., Al-Abdullah I. Ulinastatin is a novel protease inhibitor and neutral protease activator. Transpl Proc 2008, 40:387-389.
8. Pugia M., Lott J. Pathophysiology and diagnostic value of urinary trypsin inhibitors. Clin Chem Lab Med 2005, 43:1-16.
9. Tsujino T., Komatsu Y., Isayama H., Hirano K., Sasahira N., Yamamoto N., et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005, 3:376-383.
10. Chen S., Wang J. Chin J Digestion 2002, 2:70-74.
11. Chen H., He M., Li Y. Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study. Chin Med J (Engl) 2009, 122:883-888.
12. Aihara T., Shiraishi M., Hiroyasu S., Hatsuse K., Mochizuki H., Seki S., et al. Ulinastatin, a protease inhibitor, attenuates hepatic ischemia/reperfusion injury by downregulating TNF-alpha in the liver. Transpl Proc 1998, 30:3732-3734.
13. Okuhama Y., Shiraishi M., Higa T., Tomori H., Taira K., Mamadi T., et al. Protective effects of ulinastatin against ischemia-reperfusion injury. J Surg Res 1999, 82:34-42.
14. Huang Y., Xie K., Zhang J., Dang Y., Qiong Z. Prospective clinical and experimental studies on the cardioprotective effect of ulinastatin following severe burns. Burns 2008, 34:674-680.
15. O'Neill L., Bowie A. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 7:353-364.
16. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999, 162:3749-3752.
17. Crouser E., Exline M., Knoell D., Wewers M. Sepsis: links between pathogen sensing and organ damage. Curr Pharm Des 2008, 14:1840-1852.
18. Williams D., Ha T., Li C., Kalbfleisch J., Schweitzer J., Vogt W., et al. Modulation of tissue Toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit Care Med 2003, 31:1808-1818.
19. Duan Z., Gu W., Zhang L., Du D., Hu P., Huang J., et al. Clinical relevance of the TLR4 11367 polymorphism in patients with major trauma. Arch Surg 2009, 144:1144-1148.
20. Barber R., Aragaki C., Rivera-Chavez F., Purdue G., Hunt J., Horton J. TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet 2004, 41:808-813.
21. Thomas N., Umstead T., Phelps D. Altered chemokine response in an animal model of multiple organ dysfunction syndrome induced by zymosan. J Pediatr Surg 2005, 40:464-469.
22. Garrido A.G., de Figueiredo L.F.P., e Silva M.R. Experimental models of sepsis and septic shock: an overview. Acta Cirurgica Brasileira 2004, 19:82-88.
23. Dyson A., Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting?. Crit Care Med 2009, 37:S30-S37.
24. Vincent J., Sun Q., Dubois M. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002, 34:1084-1093.
25. Bernard G., Vincent J., Laterre P., LaRosa S., Dhainaut J., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
26. Finfer S., Ranieri V., Thompson B., Barie P., Dhainaut J., Douglas I., et al. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008, 34:1935-1947.
27. Spielmann S., Kerner T., Ahlers O., Keh D., Gerlach M., Gerlach H. Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand 2001, 45:364-370.
28. Barton R., Rothlein R., Ksiazek J., Kennedy C. The effect of anti-intercellular adhesion molecule-1 on phorbol-ester-induced rabbit lung inflammation. J Immunol 1989, 143:1278-1282.
29. Frink M., van Griensven M., Kobbe P., Brin T., Zeckey C., Vaske B., et al. IL-6 predicts organ dysfunction and mortality in patients with multiple injuries. Scand J Trauma Resusc Emerg Med 2009, 17:49.
30. Law M., Cryer H., Abraham E. Elevated levels of soluble ICAM-1 correlate with the development of multiple organ failure in severely injured trauma patients. J Trauma 1994, 37:100-109. discussion 109-10.